GLP-1 Drugs May Treat Rare Genetic Obesity, Japanese Study Finds

A groundbreaking study from Japanese researchers demonstrates that three popular GLP-1 drugs—semaglutide, tirzepatide, and retatrutide—could provide new treatment options for rare and hard-to-treat genetic obesity. Published in the International Journal of Obesity on 21 February 2026, the research tested these medications in mice lacking the Melanocortin 4 receptor (MC4R), a key brain receptor for hunger and energy balance. This finding opens doors for patients with monogenic obesity that begins at birth, where current options are limited.

What Is MC4R Deficiency and Why Is It Challenging?

MC4R is a receptor in the brain that receives signals to regulate hunger and energy expenditure. Genetic mutations in the MC4R gene disrupt this balance, leading to hyperphagia—an insatiable hunger and abnormal food-seeking behaviors. Affected individuals develop severe obesity from early childhood, often accompanied by insulin resistance, high cholesterol, elevated triglycerides, and liver stress markers like AST and ALT.

These cases represent rare monogenic forms of obesity, distinct from common obesity driven by lifestyle, hormones, or family habits. As Chennai-based diabetologist Dr. V. Mohan notes, "These kinds of genetic forms of obesity are what are called monogenic forms of obesity. They are extremely rare in humans. I myself may have seen only one or two such cases in my lifetime." Traditional treatments are scarce, making GLP-1 drugs a potential breakthrough.

Genetic Obesity vs. Common Obesity: Key Differences

• Onset: Genetic cases start at birth or age 1-2 due to faulty appetite regulation, not overeating.
• Symptoms: Hyperphagia, rapid weight gain, metabolic complications like insulin resistance.
• Prevalence: Extremely rare, unlike polygenic or lifestyle-related obesity affecting millions.

The Study: Testing GLP-1 Drugs in MC4R-Deficient Mice

Researchers Kosuke Hitaka, Takumi Sugawara, Mitsuharu Matsumoto, and Yasunori Nio used specially bred mice without a functional MC4R gene. These mice mimic human genetic obesity, developing severe obesity young with hyperphagia, insulin resistance, high lipids, and liver issues—faster than diet-induced models that require months of high-fat feeding.

The mice received daily injections of semaglutide, tirzepatide, or retatrutide for 21 days. Results showed significant weight reduction:

• Semaglutide: 19.7% body weight loss
• Tirzepatide: 31.6% body weight loss
• Retatrutide: 24.1% body weight loss

The weight loss patterns aligned closely with human clinical trials, including some lean mass reduction. This rapid model accelerates anti-obesity drug testing, as noted by the authors.

How Do These GLP-1 Drugs Work?

GLP-1 receptor agonists mimic the gut hormone GLP-1, which slows stomach emptying (keeping food longer for fullness), boosts insulin release, and lowers blood sugar. They're approved for type 2 diabetes and obesity.

Semaglutide

Developed by Novo Nordisk (brands: Ozempic, Wegovy, Rybelsus), it targets only the GLP-1 receptor, reducing appetite and promoting satiety.

Tirzepatide

From Eli Lilly, it activates GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), enhancing blood sugar control and yielding greater weight loss via dual action.

Retatrutide

Also Eli Lilly's, still in development, it targets GLP-1, GIP, and glucagon for broader metabolic effects, including energy balance.

Semaglutide and tirzepatide are available in India; retatrutide is expected soon.

Expert Insights on the Findings

"What is exciting is that newer GLP-1 medicines like semaglutide and tirzepatide seem to still cause meaningful weight loss even when this appetite switch is not working normally." — Dr. Rajiv Kovil, Head of Diabetology at Zandra Healthcare, Mumbai

Dr. Kovil highlights traditional MC4R-targeted therapies like Imcivree (setmelanotide), FDA-approved in 2020 for Bardet-Biedl syndrome and similar deficiencies in patients aged 2+. Imcivree directly activates the brain's appetite pathway. GLP-1 drugs bypass this by acting peripherally on gut-brain signals.

Dr. Mohan cautions: "Results in mice may not always directly apply to people." He differentiates rare genetic cases from common obesity.

Implications for Patients with Genetic Obesity

Who Might Benefit?

Those with confirmed MC4R mutations or similar monogenic obesity, especially with early-onset severe obesity and hyperphagia. Genetic testing is crucial before considering GLP-1 therapy.

What to Discuss with Your Doctor

• Genetic confirmation via sequencing.
• Baseline metabolic panel (insulin, lipids, liver enzymes).
• Dosing: Start low, titrate based on tolerance.
• Monitoring: Weight, blood sugar, side effects like nausea or GI issues common with GLP-1s.

Apps like Shotlee can help track medication schedules, symptoms, and side effects for better doctor discussions.

Safety Considerations

GLP-1 drugs are generally safe but can cause GI upset, lean mass loss, or rare pancreatitis. In genetic obesity, monitor for sustained efficacy despite MC4R issues. Not first-line for common obesity.

Comparisons: GLP-1 Drugs vs. Traditional Genetic Therapies